Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab with or without ISA101b in HPV16-positive oropharyngeal cancer
2018-000789-13Phase 2Terminated
- Sponsor
- ISA Pharmaceuticals
- Start
- Jul 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in oropharyngeal cancer comparing ISA101b + cemiplimab with Placebo + cemiplimab (2 arms). Primary endpoint: Duration of response. Started Jul 2018; status: terminated.
02
Drugs
cemiplimabSLP-HPV-01
03
Conditions
oropharyngeal cancer
Beyond the preview
Go deeper on 2018-000789-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000789-13.